Company intelligence / Profile preview

Ionova Biotherapeutics

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Ionova Biotherapeutics is a clinical-stage biotechnology company dedicated to the discovery and development of innovative precision oncology medicines. The company focuses on creating highly selective small molecule inhibitors that target key drivers of cancer growth, including FGFR, EGFR, and KRAS. Its lead candidate, INV-1122, is a potent FGFR inhibitor currently in Phase 2 clinical trials for patients with advanced solid tumors. With research and development facilities in both Beijing and San Diego, Ionova leverages a global network of expertise to accelerate its pipeline. The company is backed by prominent life science investors and aims to provide transformative therapies for cancer patients worldwide.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Ionova Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ionova Biotherapeutics.

Explore the full profile